NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies

NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.

Read news story

  1. New lung cancer treatment option approved by NICE

    Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).



NICE Annual Conference 2019

9 May 2019, Hilton Manchester Deansgate

Press and media

Contact the press office: 0300 323 0142 |